Saatchi reportedly wins Levitra DTC work

Share this article:

The Saatchi & Saatchi Consumer Healthcare unit of Publicis Groupe has won the creative duties for Levitra, AdWeek.com reported late Thursday.
Levitra, which is now co-promoted by Schering-Plough and GlaxoSmithKline, has been in review for the past several weeks.
CommonHealth's Quantum previously held the account, but was not listed among the groups who were pitching. A spokeswoman for CommonHealth declined to comment to MM&M about the review this week
Estimated billings are $90 million.
The other finalists were Omnicom Group shops BBDO and Merkley + Partners, both in New York, according to AdWeek. DDB, another Omnicom shop, initially pursued the business but withdrew before final presentations, the report stated.
Bayer and GSK co-promoted Levitra since its launch in 2003, but earlier this year Bayer agreed to turn over marketing rights for most of its prescription drug products to Schering-Plough.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.